Evidence map›Paper›PMID 35972200›Full record

ArticleJournal of primary care & community health

Human Papillomavirus Prevalence and Vaccination Rates Among Users of Pre-Exposure Prophylaxis for Human Immunodeficiency Virus Prevention.

Paul Rotert, Christopher Wheldon, Jenn Kownack, Zoe Sullivan-Blum, Brendan Cokingtin, Karishma Khetani, Kavindu Ndeti, Kevin Skyes, Megha Ramaswamy

Open access · goldAbstract read
In one paragraph

Article in Journal of primary care & community health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Paul RotertUniversity of Kansas Medical Center, Kansas City, KS, USA.
Christopher WheldonTemple University, Philadelphia, PA, USA.
Jenn KownackUniversity of Kansas Medical Center, Kansas City, KS, USA.
Zoe Sullivan-BlumUniversity of Kansas Medical Center, Kansas City, KS, USA.
Brendan CokingtinCleveland Clinic Foundation, Cleveland, OH, USA.
Karishma KhetaniRutgers New Jersey School of Medicine, Newark, NJ, USA.
Kavindu NdetiUniversity of Kansas Medical Center, Kansas City, KS, USA.
Kevin SkyesUniversity of Kansas Medical Center, Kansas City, KS, USA.ORCID 0000-0001-9379-3406
Megha RamaswamyUniversity of Kansas Medical Center, Kansas City, KS, USA.ORCID 0000-0003-4167-9024
University of Kansas Medical Center · USCleveland Clinic · USRutgers, The State University of New Jersey · USTemple University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOur study provides data on the prevalence of human papillomavirus (HPV) related disease and vaccination rates among users of pre-exposure prophylaxis (PrEP) in a primary care clinic. Results highlight an opportunity to partner HIV and HPV prevention efforts.

methodsThis is a retrospective chart review of PrEP patients in an urban Midwestern Family Medicine clinic. We conducted univariate analyses for HPV vaccination status and the prevalence of any HPV-related disease. We then examined bivariate relationships between vaccination status and insurance coverage, provider type, and age.

resultsOf all 78 PrEP patients identified, 21.8% (n = 17) were vaccinated. Of the 59 patients 45 years or younger, 28.8% (n = 17) were vaccinated. There was no association between insurance or provider type and vaccination status. Patients 26 years or younger were 3 times more likely to be vaccinated than those ages 27 to 45 (56.3% vs 18.6%,

conclusionsDespite ongoing risk of HPV infection and frequent interaction with the medical system, this study found most PrEP users continue to be unvaccinated. This is a significant missed opportunity for HPV prevention. With the FDA approval of the HPV vaccine for individuals age 9 to 45, PrEP patients in this age range would benefit from clinicians partnering HPV vaccination with PrEP prescribing.

Indexed as

AlphapapillomavirusHIV InfectionsPapillomavirus InfectionsPapillomavirus VaccinesPre-Exposure ProphylaxisAdolescentAdultChildHIVHumansMiddle AgedPapillomaviridaePrevalenceRetrospective StudiesVaccinationYoung AdultPapillomavirus VaccinesHPV prevalenceHPV vaccineMSMPrEPretrospective chart review

Identifiers

PMID35972200
PMCPMC9386814
OpenAlexW4293063234

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.